Oragenics (OGEN) Competitors

Oragenics (NYSE:OGEN) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, community ranking, profitability and media sentiment.

Does the media favor OGEN or CING?

In the previous week, Cingulate had 4 more articles in the media than Oragenics. MarketBeat recorded 7 mentions for Cingulate and 3 mentions for Oragenics. Cingulate's average media sentiment score of 0.39 beat Oragenics' score of 0.00 indicating that Cingulate is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oragenics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cingulate	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more risk & volatility, OGEN or CING?

Oragenics has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500. Comparatively, Cingulate has a beta of -0.83, meaning that its share price is 183% less volatile than the S&P 500.

Do analysts rate OGEN or CING?

Cingulate has a consensus price target of $16.00, indicating a potential upside of 267.82%. Given Cingulate's stronger consensus rating and higher probable upside, analysts clearly believe Cingulate is more favorable than Oragenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oragenics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cingulate	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

Which has higher valuation and earnings, OGEN or CING?

Oragenics has higher revenue and earnings than Cingulate.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oragenics	$40K	116.02	-$20.66M	-$1.70	-0.13
Cingulate	N/A	N/A	-$23.53M	N/A	N/A

Does the MarketBeat Community favor OGEN or CING?

Cingulate received 11 more outperform votes than Oragenics when rated by MarketBeat users. Likewise, 78.57% of users gave Cingulate an outperform vote while only 0.00% of users gave Oragenics an outperform vote.

Company	Underperform	Outperform
Oragenics	Outperform Votes No Votes	Underperform Votes 49 100.00%
Cingulate	Outperform Votes 11 78.57%	Underperform Votes 3 21.43%

Is OGEN or CING more profitable?

Cingulate's return on equity of -570.20% beat Oragenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oragenics	N/A	-2,087.95%	-486.56%
Cingulate	N/A	-570.20%	-236.15%

Do institutionals & insiders hold more shares of OGEN or CING?

18.7% of Oragenics shares are held by institutional investors. Comparatively, 41.3% of Cingulate shares are held by institutional investors. 10.1% of Oragenics shares are held by insiders. Comparatively, 17.1% of Cingulate shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Cingulate beats Oragenics on 12 of the 15 factors compared between the two stocks.